Charles Schwab Investment Management Inc. Has $925,000 Stock Holdings in Perspective Therapeutics, Inc. $CATX

Charles Schwab Investment Management Inc. grew its position in Perspective Therapeutics, Inc. (NYSE:CATX) by 6.7% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 434,085 shares of the company’s stock after purchasing an additional 27,119 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.59% of Perspective Therapeutics worth $925,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the business. Deerfield Management Company L.P. Series C increased its position in Perspective Therapeutics by 4.3% during the fourth quarter. Deerfield Management Company L.P. Series C now owns 2,938,754 shares of the company’s stock worth $9,375,000 after buying an additional 120,991 shares during the last quarter. Octagon Capital Advisors LP increased its position in Perspective Therapeutics by 62.1% during the fourth quarter. Octagon Capital Advisors LP now owns 2,304,752 shares of the company’s stock worth $7,352,000 after buying an additional 882,528 shares during the last quarter. Millennium Management LLC acquired a new position in Perspective Therapeutics during the fourth quarter worth approximately $4,132,000. Two Sigma Investments LP acquired a new position in Perspective Therapeutics during the fourth quarter worth approximately $2,075,000. Finally, Velan Capital Investment Management LP acquired a new position in Perspective Therapeutics during the fourth quarter worth approximately $1,595,000. Institutional investors own 54.66% of the company’s stock.

Perspective Therapeutics Trading Down 1.2%

Shares of Perspective Therapeutics stock opened at $3.32 on Wednesday. The business has a 50-day moving average price of $3.76 and a two-hundred day moving average price of $2.97. Perspective Therapeutics, Inc. has a 1-year low of $1.60 and a 1-year high of $16.31.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the company. Lifesci Capital raised Perspective Therapeutics to a “strong-buy” rating in a research report on Saturday, July 12th. Royal Bank Of Canada upgraded shares of Perspective Therapeutics from an “outperform” rating to a “moderate buy” rating and boosted their target price for the company from $15.00 to $16.00 in a research report on Tuesday, June 3rd. Wedbush reiterated an “outperform” rating and issued a $11.00 price target on shares of Perspective Therapeutics in a research note on Monday, June 23rd. Truist Financial dropped their price target on Perspective Therapeutics from $10.00 to $8.00 and set a “buy” rating for the company in a research note on Wednesday, May 14th. Finally, B. Riley reiterated a “buy” rating and issued a $12.00 price target (up from $9.00) on shares of Perspective Therapeutics in a research note on Monday, June 23rd. Three equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $12.56.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.